We need a robust biopharma industry, and I think everyone agrees to that, investing in rare diseases.

H.R. 3, unfortunately, is an overreach, and unfortunately it gives me the impression, for those in the package, that Congress is seemingly willing to let American patients suffer.

The status quo is not acceptable. Congress must act to ensure that the American people have access to and can afford the treatments that they need.

Policies like referencing pricing and government price-settings will effectively turn our biopharma industry to a risk-averse, think-inside-the-box-rather-than-outside-the-box commodity industry.

So we know the loser here is going to be the American public if we don't get a bill to the President's desk for signature.

Healthcare is a right for everyone, and access to prescription medication should not be reserved as a privilege only for the wealthy few.

If I could, I want to ask a last question to Dr. Gupta because the United States, we are still--across the country still experiencing a wave of drug overdoses at a higher rate than we have ever seen before.

This is nothing but a politically driven agenda aimed at ending the use of coal and natural gas in this country.

There is--this is nothing but a politically driven agenda aimed at ending jobs and the use of coal and natural gas in this country.

We agree the world needs to reduce its carbon emissions but according to experts, reaching net-zero emissions will be impossible without carbon capture.

Thank you again, Administrator Regan, not only for appearing before us, but also our conversation yesterday to get to know each other.